Objective: While thymectomy is an accepted treatment for myasthenia gravis (MG), video-assisted thoracoscopic surgery (VATS) thymectomy has recently become a popular surgical treatment, especially for non-thymomatous MG (NTMG). This study aims to compare the results of VATS thymectomy and trans-sternal thymectomy, and identify prognostic factors in NTMG patients after thymectomy. Methods: A 10-year retrospective review (January 1995 to December 2004) of 60 consecutive thymectomies (22 trans-sternal thymectomies and 38 VATS thymectomies) of NTMG patients performed in a university teaching hospital was undertaken. Results: There were 43 female patients and 17 male patients with a median MG-onset age of 25 years (range: 5-78 years). Median follow-up time was 44 months. VATS thymectomy patients had a shorter hospital stay than the trans-sternal thymectomy patients (5.6 days vs 8.1 days, p = 0.008). There was no other statistically significant difference between the two operative methods in NTMG patients, including intensive care unit (ICU) stay, ventilator support time, operative time, postoperative status, complete stable remission (CSR) rate, morbidity and mortality. Three prognostic factors associated with better remission rate were hyperthyroidism ( p = 0.003), age <40 years ( p = 0.022) and the presence of thymic hyperplasia ( p = 0.041). Other factors, including gender, disease duration, preoperative MG severity, acetylcholine receptor antibody, perioperative therapy and operative methods (32% vs 36%, p = 0.91, 95% confidence interval (CI) = 0.27-3.21) were not statistically relevant to better remission rate. Conclusions: VATS thymectomy is more advantageous for NTMG patients because of shorter hospital stay, less tissue injury, better cosmetic result and equivalent CSR rate. NTMG patients aged <40 years with hyperthyroidism and a histologic diagnosis of lymphofollicular hyperplasia have better chances of remission after thymectomy. #
Introduction
Myasthenia gravis (MG) is an autoimmune disease with a prevalence of 50-125 cases per million population [1] . Thymectomy can eradicate the sites of self-sustaining autoimmune reaction and it is currently regarded as an effective treatment [2] . While the thymus is mainly located in the anterior mediastinum, it may be unencapsulated and invisibly distributed in the cervical and pericardial fat from the level of the neck to the diaphragm [3] . Because the principle of thymectomy for MG is the radical removal of thymic tissue, different medical centres practice different methods [3] . Minimally invasive thymectomy is currently the more popular method because of its comparable safety, efficacy, cosmetic consideration, less degree of tissue damage and lower hospital cost. However, a prospective randomised trial to evaluate the efficacy of different thymectomy methods for MG is still lacking.
In our institution, all non-thymomatous MG (NTMG) patients have been undergoing video-assisted thoracoscopic surgery (VATS) thymectomy since December 1999. The long patient follow-up time and adequate patient number has allowed for a retrospective comparison between VATS thymectomy and trans-sternal thymectomy in terms of efficacy and safety, particularly the complete stable remission (CSR) rate, and the identification of prognostic factors of thymectomy in NTMG patients.
Materials and methods

Patients
From January 1995 to December 2004, 60 consecutive patients who underwent thymectomy for NTMG were retrospectively identified by review of records at the National www.elsevier.com/locate/ejcts European Journal of Cardio-thoracic Surgery 37 (2010) [7] [8] [9] [10] [11] [12] Taiwan University Hospital (NTUH). The diagnosis of MG was based on clinical symptomatology and one of the following examinations: Tensilon test, serum acetylcholine receptor (AChR) antibody study, repetitive stimulation test or singlefibre electromyographic study. The patients had a preoperative contrast-enhanced chest computed tomography (CT) study and those with thymoma were excluded.
The patients' preoperative clinical status was classified according to the MG Foundation of America (MGFA) clinical classification [4] . NTMG patients at NTUH underwent transsternal thymectomy prior to December 1999 and VATS thymectomy after December 1999. The same physician evaluated all of the patients on postoperative follow-up at least four times per year. Muscle weakness and the involved sites were carefully examined. The therapeutic response to thymectomy was compared with the patient's preoperative status and assessed according to the MGFA post-intervention status [4] .
CSR was defined as the absence of MG during a particular time. There was no weakness or any muscle-related symptoms or signs of MG for at least 1 year, and the patient did not receive any therapy on careful examination by a skilled evaluator of neuromuscular diseases. Isolated weakness on eyelid closure was accepted. An 'improved' postoperative disease status in this study included CSR, pharmacologic remission, minimal manifestations and improved in status in the MGFA post-intervention status. Definitions of postoperative disease status 'unchanged' and 'worse' were according to the MGFA post-intervention status.
Clinicopathologic parameters, including sex, MG-onset age, disease duration, follow-up time, underlying disease, preoperative MGFA classification, serum AChR antibody, medical treatment before surgery, intensive care unit (ICU) stay, ventilator support time, total duration of hospital stay, operative method, operative time, blood loss, blood transfusion, MGFA post-intervention status, morbidity, mortality and pathologic classification were collected from chart review and by telephone interviews.
Surgical technique of VATS thymectomy
Surgery was performed under general anaesthesia using a double-lumen endotracheal tube intubation. The patient was placed in a left semi-decubitus position with right lung deflation. A 10 mm incision was made at the eighth intercostal space, posterior axillary line for 10-mm, 308 telescope insertion. Two 15-mm skin incisions were made at the third intercostal space, mid-axillary line and at the seventh intercostal space, anterior axillary line, as instrument ports. The entire procedure was then performed with conventional long instruments.
The lower horn of the thymus was identified and dissected off the pericardium. The pericardial fat was also simultaneously removed. With traction of the thymic tissue, the thymus was separated from the pericardium upwardly. The thymic vein was identified at the level of the left brachiocephalic vein, and then clipped and divided by endo-clips. The bilateral upper horns of the thymus were then bluntly dissected from the peripheral soft tissue by gentle retraction of the thymus. After complete removal of the thymus, two Fr. 28 chest tubes were placed in the right pleural cavity and anterior mediastinum through the midaxillary line camera port and anterior axillary line instrument working port. The surgical specimens were routinely sent for histopathologic examination.
Surgical technique of trans-sternal thymectomy
Surgery was performed under general anaesthesia using a single-lumen endotracheal tube intubation. The patient was placed in a supine position and thymic tissues with pericardial fat were removed radically by conventional instruments through median sternotomy. Two Fr. 28 chest tubes were placed in the anterior mediastinum, while the specimens were sent for histopathologic examination.
Statistical analysis
Categorical variables were presented by frequency (%) and analysed by Fisher's exact test or by Pearson's chi-square test. Continuous variables were expressed as mean AE stanstandard deviation (SD) and analysed by the two-sample ttest. Considering the follow-up time, the impact of prognostic factors was estimated by the Kaplan-Meier survival curves and Cox proportional hazards regression model, calculating odds ratio with 95% confidence intervals. A p-value <0.05 was considered statistically significant.
Results
Of the 60 patients, 22 underwent trans-sternal thymectomy and 38 underwent VATS thymectomy. The median MGonset age was 25 years (range: 5-78 years; 17 males, 43 females) and the median preoperative disease duration was 6 months (range: 1-300 months). Median follow-up time was 44 months (range: 12-131 months; mean: 54.4 AE 35.8 months). Twelve patients (20%) had underlying hyperthyroidism. The MGFA classification of the study patients was mainly classes I and II (52 patients, 87%). Half of them received anti-cholinesterase treatment while the rest received anti-cholinesterase with steroids (50% vs 50%) prior to surgery. In addition, two patients received plasma exchange preoperatively because of MG crisis. None of the 38 VATS thymectomy patients had to convert to conventional thymectomy.
The demographic and preoperative data are summarised in Table 1 . The two groups were significantly different in preoperative MGFA class V ( p = 0.02). In the trans-sternal thymectomy group, three patients were classified as MGFA class V before the operation, but none in the VATS thymectomy group. These three patients suffered from respiratory failure preoperatively and had to be intubated and given ventilatory support. The two groups did not significantly differ in other demographic and preoperative data, including sex, MG-onset age, disease duration before operation, underlying hyperthyroidism, anti-AChR antibody and preoperative medication.
Postoperative data of the two groups are summarised in Table 2 . Postoperative complications occurred in three patients (5%), including prolonged intubation in two and brachial plexus injury in one. The criteria for prolonged intubation were defined as intubation time of more than 2 days after the surgery. In the trans-sternal thymectomy group, one patient was classified as MGFA class V and had MG crisis and respiratory failure before the surgery. Extubation was performed 6 days postoperatively. Another patient was extubated 5 days after VATS thymectomy because of old age (69 years) and poor cough ability. A 20-year-old woman had right brachial plexus injury after VATS thymectomy because of an inappropriate operative position. During the surgery, she was left in the left decubitus position with her right arm in 908 of abduction, flexion and mild external rotation for 2 h. She presented with right interosseous muscle atrophy and ulnar side numbness 1 week postoperatively, and received physical therapy thereafter. She recovered 2 months later. No patient had phrenic nerve or recurrent laryngeal nerve injury, and there was no postoperative pneumonia, sepsis or mortality.
The lengths of hospital stay were significantly different between the trans-sternal thymectomy and VATS thymectomy groups (8.1 days vs 5.6 days, p = 0.008). There were no other significant differences between the two groups, including achieving CSR rate.
Possible prognostic factors for NTMG patients who underwent thymectomy were evaluated. Those potentially affecting outcomes were estimated by the Kaplan-Meier survival curves and Cox proportional hazards regression model (Table 3) . Patients with an MG-onset age <40 years ( p = 0.022), hyperthyroidism ( p = 0.003) and thymic hyperplasia ( p = 0.041) were associated with a higher probability of achieving CSR. The operative method was not a significant prognostic factor after thymectomy in NTMG patients ( p = 0.91, 95% CI: 0.27-3.21) (Fig. 1 ).
Discussion
VATS thymectomy is performed as the standard procedure for NTMG patients in the NTUH since 1999, and it has provided a new approach for thymectomy in MG patients since the early 1990s [5] ; and its advantages include improved cosmetic results and reduced postoperative pain, incisionrelated morbidity, hospital stay and low costs. However, there are still many different thymectomy methods used in different medical institutions, including trans-sternal thymectomy, trans-cervical thymectomy and video-assisted thoracoscopic extended thymectomy (VATET, with cervical incision to remove the thymus in the neck) [3] . The reason for the various operative methods is that the thymus is widely distributed in the neck and mediastinum and that a standard surgical approach remains controversial [3] . Aside from the advantage of minimally invasive thymectomy methods in NTMG patients, the most important consideration is the CSR rate, which is related to the radical removal of thymic tissue [6] . Therefore, physicians have to find a balance between minimally invasive techniques and radical removal of thymic tissue.
A prospective non-randomised study reveals that VATET may be effective and have a CSR rate similar to that of the trans-sternal approach [7] . Some studies that retrospectively reviewed the efficacy of VATS thymectomy and the CSR rate have shown that the CSR rate is similar to that in the other thymectomy methods [8] [9] [10] [11] [12] . However, due to different demographic data, different institutions and different MG classification methods, it is difficult to compare the CSR rate between different studies. This retrospective study compares VATS thymectomy with trans-sternal thymectomy with similar demographic population data in the same institution.
This study demonstrates that VATS thymectomy is a advantageous procedure for treating NTMG patients compared to the trans-sternal approach. The crude CSR rate is 32% in a 38.5-month mean follow-up time, which is an acceptable CSR rate and similar to other studies [8] [9] [10] [11] [12] . The Kaplan-Meier cumulative estimation of the CSR rate ( Fig. 1 ) reveals no significant difference compared to trans-sternal thymectomy ( p = 0.91, 95% CI: 0.27-3.21). In fact, the VATS thymectomy group has a trend of better probability of attaining CSR in this curve. No statistical significance may be associated with a small patient number. In addition, the MGFA postoperative status improved in 90% patients in the VATS thymectomy group, compared to 77% in the trans-sternal thymectomy group ( p = 0.2, Table 2 ). The only significantly difference in the postoperative data between the two groups is the shorter hospital stay in VATS thymectomy patients. Reduced hospital stay may have been influenced by policy changes, since hospital stay has been reduced in the recent decade all over the world. However, the shorter hospital stay in the VATS thymectomy group is also reported by other studies [13] . It may be more relevant in terms of minimal chest wall trauma and less postoperative pain.
The amount of blood loss was less in the VATS group (169.2 AE 59.7 ml vs 177 AE 36.9 ml) despite the greater receiving transfusion rate (8% vs 0%). The mean blood loss was less in the VATS group because of the minimal surgical wound and less tissue injury. In the VATS group, three patients received blood transfusion intra-operatively. Among the three, two experienced thymic vein laceration and one had right internal mammary vein injury. The vital signs were within normal range during the operation, and all of them underwent haemostasis successfully with suturing and clipping without conversion to the open method thymectomy. Based on experience, trans-sternal thymectomy is safe in approaching vessels because of the large operative field. However, the VATS approach is also acceptable in considering safety in approaching the thymic vessel.
One patient had brachial plexus injury secondary to malposition of VATS thymectomy. She was the fourth patient in the first year of VATS thymectomy at the NTUH. The brachial plexus injury may be related to the large degree of right arm abduction. After conservative treatment, her symptoms were resolved 2 months post-surgery. Brachial plexus injury is the most common nerve injury associated with thoracic surgery [14, 15] . It is a catastrophic complication in minimal-invasive surgeries that can be prevented easily by the proper patient positioning including the shoulder joint placed no more than 908 abduction or 608 abduction accompanied by external rotation, the head in neutral position and a roll placed under the axilla [15] . Abbreviations: AChR, acetylcholine receptor; CSR, complete stable remission; MGFA, myasthenia gravis foundation of America; TS, trans-sternal thymectomy; VATS, video-assisted thoracoscopic surgery. Some differences between the two groups may still influence postoperative outcome in this study. The preoperative MGFA classification is more severe in the transsternal thymectomy group than the VATS thymectomy group (Table 1) . Some studies reveal the relation of severe preoperative MG status with better outcome after thymectomy [11, 16] . In fact, the influence of preoperative MGFA classification is not yet clear, but it is a possible factor that may influence outcome. On the other hand, the two groups of patients have been operated in sequence. Therefore, the learning curve accomplished with trans-sternal thymectomy has an impact on the VATS approach, as well as in pre-and postoperative management. Only a randomised prospective study can scientifically and clearly compare the difference between the VATS and trans-sternal groups. Nonetheless, the acceptable CSR rate in this study still suggests that VATS thymectomy is the more preferred method.
The results of previous studies for VATS thymectomy are summarised in Table 4 [8] [9] [10] [11] [12] . The crude CSR rate in other retrospective studies of VATS thymectomy ranges from 14% to 36%, with one series achieving an excellent CSR rate of 60% in 37 patients completing 6 years of follow-up time [12] . Postoperative improvement ranges from 81% to 96%, while the duration of hospital stay ranges from 1.6 to 5.6 days and the range of morbidity rate is 3-11%. Among a total of 274 patients in six studies, only two suffered from uncontrolled intra-operative bleeding that needed to convert to the open method thymectomy (1%). The longer hospital stay in the current study may be related to a different health insurance system.
In addition, 45% of the patients were preoperatively classified as MGFA class I. This percentage is larger than in other groups. The role of thymectomy for ocular NTMG patients remains controversial [17] . Ocular MG is not a lifethreatening disease and thymectomy may be a risky procedure. However, diplopia and ptosis may impair the quality of life. Some patients depend on immunosuppressant drugs for a long time. Moreover, the disease may progress to more advanced stages. With the development of minimal invasive thymectomy, more surgeons tend to operate on pure ocular MG patients after failed medical therapy. A few retrospective studies have evaluated the efficacy of thymectomy for pure ocular MG and concluded that thymectomy is beneficial for such patients [17, 18] . Schumm et al. and Roberts et al. both suggest that thymectomy should be considered in pure ocular MG patients after medical treatment for 6 months [17, 18] . In the current study, all MGFA class I patients underwent VATS thymectomy after medical therapy failed for a mean duration of 33.75 months. Sixteen of seventeen patients (94%) in this group achieved CSR or improvement after VATS thymectomy, with a mean follow-up of 43 months.
Other results in this study are similar to other VATS thymectomy studies. According to these, the acceptable CSR rate, high improvement rate, short hospital stay, low conversion rate, low morbidity rate and no mortality demonstrate that VATS thymectomy is a safe and effective method for NTMG patients.
Using the Cox proportional hazards regression model, three significant prognostic factors affecting the CSR rate in NTMG patients are identified: younger onset age ( p = 0.022), presence of thymic hyperplasia ( p = 0.041) and hyperthyroidism ( p = 0.003). Many studies report that patients with an earlier onset age have better prognosis after thymectomy [12, [19] [20] [21] [22] [23] . A higher CSR rate in MG patients with thymic hyperplasia who underwent thymectomy has also been reported in several studies [7, 19, 22] .
A higher rate of remission in MG patients with hyperthyroidism has not yet been reported. Hyperthyroidism occurs in approximately 2-18% of MG patients [24] . Trabelsi and colleagues report that treatment of hyperthyroidism improved MG symptoms in two cases [24] . In addition, Kondo et al. report that thymic hyperplasia resolved as thyroid function was normalised by anti-thyroid medication in three cases [25] . In this study, all 11 patients with hyperthyroidism received antithyroid medication. Whether the better prognosis is related to anti-thyroid drugs or other immunologic factors warrant further investigation.
There are some other good prognostic factors reported by previous studies, including short disease duration and the patient's preoperative medication with anti-cholinesterase alone [11, 12] . The current study also shows a better CSR rate with these two prognostic factors, but not statistically significant. Hence, these good prognostic factors may be helpful in further patient selection.
In conclusion, minimally invasive thymectomy is an important issue in NTMG. To find a balance between a minimal surgical wound and good CSR rate, VATS thymectomy is advantageous because of shorter hospital stay, less tissue injury, better cosmetic results and equivalent CSR rate as the trans-sternal approach. Our retrospective study is based on a historical comparison of two subsequent periods. Multiple factors might have biased the results. Therefore, further randomised controlled studies on the result of different surgical treatment of NTMG patients may be necessary. NTMG patients aged <40 years with concurrent hyperthyroidism and pathologic diagnosis of lymphofollicular hyperplasia of a The study achieved the excellent 60% CSR rate in 37 patients who completed 6-year follow-up period.
